APS is a biotech focused on the development of treatments for mucositis, which it believes is an unmet medical need, and will now use Biomodels’ screening studies to evaluate the efficacy and define the mechanism of action of its pipeline.
By using these services APS believes it will improve its preclinical activities and help it launch its clinical programme later this year.
Aman Johar, CEO of APS, said: “We are very excited about partnering with Biomodels.This relationship allows us flexibility to customise our pre-clinical studies, maintain our clinical end-points and effectively utilise capital resources.
“A full-scale collaboration extends our research platform and provides access to leading scientists and researchers. Biomodels’ proven models reliably predict clinical success in an extremely complex field of mucositis. APS products can be the standard of care for preventing mucositis – saving over $2 billion annually in hospitalisation costs.”
The alliance has been tailored to APS’ needs as an early-stage pharmaceutical company, with Biomodels believing it represents a new business model.
Edward Fey, managing partner of Biomodels, said: “Together Biomodels and APS will finalise oral mucositis studies and also rapidly test a number of mechanistically-related therapeutic areas using appropriate validated models.
“This alliance represents a new business model for the outsourcing of pre-clinical services and is designed to fulfill the specific needs of early stage pharmaceutical companies.”